Literature DB >> 10101803

Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.

S Peller1.   

Abstract

The p53 tumor suppressor gene is frequently mutated in most human malignancies. These mutations have been associated with clinical outcome for various cancer types. Since this gene's main function is to guard the integrity of the genome, its clinical relevance, i.e. its role in carcinogenesis and chemotherapy-drug resistance, have been extensively studied. These data and the p53 protein as a potential target for new treatment strategies, are reviewed based on acquired knowledge of the structure function of the p53 protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10101803     DOI: 10.1006/scbi.1998.0100

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  10 in total

1.  Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.

Authors:  Khanh H Nguyen; Paul Hachem; Li-Yan Khor; Naji Salem; Kelly K Hunt; Peter R Calkins; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.

Authors:  Mazin Al-Salihi; Margaret Yu; David M Burnett; Amanda Alexander; Wolfram E Samlowski; Frank A Fitzpatrick
Journal:  Epigenetics       Date:  2011-08-01       Impact factor: 4.528

3.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Authors:  Lance D Miller; Johanna Smeds; Joshy George; Vinsensius B Vega; Liza Vergara; Alexander Ploner; Yudi Pawitan; Per Hall; Sigrid Klaar; Edison T Liu; Jonas Bergh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

4.  Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.

Authors:  Toshiro Niki; Takashi Kohno; Sanae Iba; Yasumitsu Moriya; Yoko Takahashi; Miyuki Saito; Arafumi Maeshima; Tesshi Yamada; Yoshihiro Matsuno; Masashi Fukayama; Jun Yokota; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

5.  Targeting cancer cells with the natural compound obtusaquinone.

Authors:  Christian E Badr; Stephanie Van Hoppe; Hawasatu Dumbuya; Lee-Ann Tjon-Kon-Fat; Bakhos A Tannous
Journal:  J Natl Cancer Inst       Date:  2013-03-11       Impact factor: 13.506

6.  Gamma-Tocotrienol Modulates Radiation-Induced MicroRNA Expression in Mouse Spleen.

Authors:  Sanchita P Ghosh; Rupak Pathak; Parameet Kumar; Shukla Biswas; Sharmistha Bhattacharyya; Vidya P Kumar; Martin Hauer-Jensen; Roopa Biswas
Journal:  Radiat Res       Date:  2016-04-29       Impact factor: 2.841

7.  Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro.

Authors:  Ming Shi; Fu-Sheng Wang; Zu-Ze Wu
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

8.  Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma.

Authors:  Pingping Mao; Mary P Hever-Jardine; Gilbert J Rahme; Eric Yang; Janice Tam; Anita Kodali; Bijesh Biswal; Camilo E Fadul; Arti Gaur; Mark A Israel; Michael J Spinella
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

9.  Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish.

Authors:  J S Chua; H P Liew; L Guo; D P Lane
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

10.  Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen.

Authors:  Lars Herfindal; Lene Myhren; Bjørn Tore Gjertsen; Stein Ove Døskeland; Gro Gausdal
Journal:  BMC Cancer       Date:  2013-07-11       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.